Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group
Efstathios S. Papageorgiou
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorPanagiotis Tsirigotis
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorMeletios Dimopoulos
Department of Clinical Therapeutics, University of Athens, Athens, Greece
Search for more papers by this authorNikolaos Pavlidis
Medical Oncology Department, Ioannina University, Ioannina, Greece
Search for more papers by this authorGeorge Fountzilas
AHEPA Hospital, Aristotle University, Thessaloniki, Greece
Search for more papers by this authorSotirios Papageorgiou
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorTheofanis Economopoulos
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorEfstathios S. Papageorgiou
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorPanagiotis Tsirigotis
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorMeletios Dimopoulos
Department of Clinical Therapeutics, University of Athens, Athens, Greece
Search for more papers by this authorNikolaos Pavlidis
Medical Oncology Department, Ioannina University, Ioannina, Greece
Search for more papers by this authorGeorge Fountzilas
AHEPA Hospital, Aristotle University, Thessaloniki, Greece
Search for more papers by this authorSotirios Papageorgiou
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorTheofanis Economopoulos
Second Department of Internal Medicine, Athens University, University General Hospital ‘Attikon’, Haidari, Greece
Search for more papers by this authorAbstract
Abstract: To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were treated with gemcitabine 1000 mg/m2 and vinorelbine 30 mg/m2 on days 1 and 8 every 3 wk for a maximum of six cycles. Fourteen patients were considered chemosensitive while eight patients were considered chemoresistant to the last treatment regimen. All 22 patients were assessed for response to treatment. Three patients (14%) achieved complete remission and eight patients (36%) had partial remission of their disease, with an overall response rate of 50%. With a median follow up of 44 months, the median time to progression (TTP) for all patients was 8.1 months while the median overall survival (OS) was 12.9 months. Toxicity was minimal and all patients were treated on an outpatient basis. The combination of gemcitabine and vinorelbine is an effective and well-tolerated regimen for patients with relapsed of refractory DLBL.
References
- 1 Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 1993; 328: 1002–1006.
- 2 Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.
- 3 Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3786–3792.
- 4 Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113: 185–187.
- 5 Bernell P, Ohm L. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br J Haematol 1998; 101: 203–204.
- 6 Sarris AH, Psyrri A, Hagemeister F, et al. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymph 2000; 39: 291–299.
- 7
Rule S,
Tighe M,
Davies S,
Johnson S.
Vinorelbine in the treatment of lymphoma.
Hematol Oncol
1998; 16: 101–105.
10.1002/(SICI)1099-1069(199809)16:3<101::AID-HON629>3.0.CO;2-# CAS PubMed Web of Science® Google Scholar
- 8 Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methyloprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Brit J Haematol 2003; 120: 970–977.
- 9 Crump M, Baetz T, Couban S, et al. Gemcitabine, Dexamethasone, and Cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma. A phase II study by the national cancer institute of Canada clinical trials group (NCIC-CTG). Cancer 2004; 101: 1835–1842.
- 10 Aviles A, Neri N, Huerta-Guzman J, Fernandez R. Gemcitbine and cisplatin in refractory malignant lymphoma. Oncology 2004; 66: 197–200.
- 11 Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23: 3–15.
- 12 Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 3–10.
- 13 Binet S, Chaineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262–266.
- 14 Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336–341.
- 15 Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organisation classification of neoplastic diseases of hematopoietic and lymphoid tissues. Am J Surg Pathol 1997; 21: 114–121.
- 16 A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994.
- 17 Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253.
- 18 Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
- 19 Lenter C. Geigy Scientific Tables (exact confidence limits for p). Switzerland: Ciba-Geigy, 1982: 89–102.
- 20 Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.
- 21 Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9: 423–431.
- 22 Hagemeister FB. Treatment of elapsed aggressive lymphomas: regimens with and without high dose therapy and stem cell rescue. Cancer Chemother Pharmacol 2002; 49: 13–20.
- 23
Lilenbaum R,
Cano R,
Schwartz M,
Siegel L,
Lutzky J,
Lewis M,
Krill E,
Barreras L,
Davila E.
Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
Cancer
2000; 88: 557–562.
10.1002/(SICI)1097-0142(20000201)88:3<557::AID-CNCR10>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 24 Natale RB. Gemcitabine-containing regimens vs others in first line treatment of NSCLC. Oncology 2004; 18: 27–31.
- 25 Sanal SM, Gokmen E, Karabulut B, Sezgin C. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J 2002; 8: 171–176.
- 26 Donadio M, Ardine M, Berruti A, Ritorto G, Fea E, Mistrangelo M, Coccorullo Z, Bergnolo P, Comandone A, Bertetto O. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 2003; 52: 147–152.
- 27 Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176.
- 28 Moskowitz CH, Bertino JR, Glassman JR. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785.
- 29 Xiros N, Economopoulos T, Valsami S, Rontogianni D, Fountzilas G, Raptis S. Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study. Leuk Res 2003; 27: 1097–1099.
- 30 Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002; 17: 621–630.
- 31 Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932.
Citing Literature
